Muscle-Associated Disorders and Clinical Applications (Muscles pt iii, BIOL1300 Lecture 12)

Muscle-Associated Disorders

Overview of Major Muscle Disorders

Muscle-associated disorders are conditions that affect the structure or function of muscles, often leading to weakness, degeneration, or impaired movement. These disorders can be genetic, autoimmune, or neurodegenerative in origin, and may have significant impacts on quality of life and life expectancy.

• Muscular Dystrophy: A group of genetic disorders characterized by progressive muscle degeneration and weakness. Approximately 300,000 people are affected globally. It is 100% fatal, with a typical life expectancy of 20-25 years.

• Myasthenia Gravis: An autoimmune disorder affecting about 1,640,000 people worldwide. Treatments are available.

• Fibromyalgia: A chronic condition affecting about 4,000,000 people in the US, characterized by widespread pain and fatigue. Treatments are available.

• Amyotrophic Lateral Sclerosis (ALS): A neurodegenerative disease affecting about 30,000 people in the US. It is 100% fatal, with death typically occurring within 2-5 years of diagnosis.

Fibromyalgia

Clinical Features and Pathophysiology

Fibromyalgia is a chronic disorder characterized by widespread musculoskeletal pain, often accompanied by fatigue, sleep disturbances, and cognitive difficulties.

• Symptoms: Pain in muscles and joints throughout the body, significant impact on mental health, and problems with memory ("fibro fog").

• Pathophysiology: Studies suggest altered pain processing in the brain, rather than direct muscle pathology. It is considered a neurological condition, though muscle anatomy is not primarily affected.

• Treatments: Physical therapy, cognitive therapy, anti-inflammatories, and exercise.

• Risk Factors: More common in women (2x as likely), typically diagnosed before age 40, associated with autoimmune diseases, trauma, stressors, and family history.

Example: A patient with fibromyalgia may experience chronic pain and fatigue, but muscle biopsies typically do not show structural abnormalities.

Myasthenia Gravis

Pathophysiology and Clinical Presentation

Myasthenia gravis is an autoimmune disorder that impairs communication between nerves and muscles, leading to muscle weakness and fatigue.

• Symptoms: Muscle weakness, especially in the eyes (ptosis), and generalized tiredness.

• Mechanism: Autoantibodies target acetylcholine (ACh) receptors at the neuromuscular junction, blocking ACh binding and impairing muscle contraction.

• Treatments: Immunosuppressants, acetylcholinesterase inhibitors, and newer therapies.

• Epidemiology: Can affect anyone; women are more likely to be affected under age 40, men more likely after age 65. Slightly more common in people of African descent.

Example: A patient with myasthenia gravis may present with drooping eyelids and muscle weakness that worsens with activity and improves with rest.

Amyotrophic Lateral Sclerosis (ALS)

Clinical Features and Disease Progression

ALS is a progressive neurodegenerative disorder affecting motor neurons, leading to muscle weakness, paralysis, and ultimately death.

• Symptoms: Progressive muscle weakness, loss of function, and eventual paralysis.

• Pathophysiology: Death of motor neurons results in loss of stimulation to muscles, causing atrophy.

• Treatments: No cure; some therapies can slow progression (e.g., physical therapy, ventilation, and recently approved medications).

• Epidemiology: More common in men, can be sporadic or familial, most cases diagnosed after age 55.

Example: A patient with ALS may initially present with muscle weakness and progress to complete paralysis, requiring ventilatory support.

Muscular Dystrophy

Genetic Basis and Clinical Manifestations

Muscular dystrophy refers to a group of inherited disorders characterized by progressive muscle degeneration and weakness, often beginning in childhood.

• Symptoms: Muscle degeneration and weakness, often apparent from birth or early childhood.

• Genetic Cause: Mutations in or absence of the dystrophin gene, which encodes a protein that links the cytoskeleton to the muscle cell membrane.

• Pathophysiology: Lack of dystrophin destabilizes muscle fibers, leading to damage and degeneration with use.

• Treatments: No cure; genetic therapies are being developed and have shown promise in recent years.

• Epidemiology: Predominantly affects males due to X-linked inheritance.

Example: Duchenne muscular dystrophy is the most common form, presenting in young boys with progressive muscle weakness and loss of ambulation by adolescence.

Summary Table: Major Muscle-Associated Disorders

Disorder	Etiology	Symptoms	Treatments	Prognosis
Muscular Dystrophy	Genetic (dystrophin gene mutation)	Progressive muscle weakness, degeneration	Supportive, genetic therapies (experimental)	Fatal (20-25 years life expectancy)
Myasthenia Gravis	Autoimmune (ACh receptor antibodies)	Muscle weakness, ptosis, fatigue	Immunosuppressants, AChE inhibitors	Variable, treatable
Fibromyalgia	Unknown, altered pain processing	Widespread pain, fatigue, cognitive issues	Physical therapy, medications, exercise	Chronic, manageable
ALS	Neurodegenerative (motor neuron loss)	Progressive weakness, paralysis	Supportive, some drugs slow progression	Fatal (2-5 years post-diagnosis)

Additional info: The notes above are based on the provided lecture slides and expanded with standard academic context for clarity and completeness.